Skip to main content

Immune Thrombocytopenic Purpura

6
Pipeline Programs
12
Companies
12
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
4
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

11 companies ranked by most advanced pipeline stage

CSL Seqirus
CSL SeqirusUK - Maidenhead
2 programs
1
1
IgPro10Phase 4
Immunoglobulin IntravenousPhase 3
ViiV Healthcare
ViiV HealthcareNC - Durham
3 programs
1
1
EltrombopagPhase 3
LGD-4665Phase 2
EltrombopagN/A
Sandoz
SandozAustria - Kundl
1 program
1
EltrombopagPhase 31 trial
Active Trials
NCT01621204Completed74Est. Aug 2019
Bayer
BayerLEVERKUSEN, Germany
1 program
1
Methylprednisolone and IVIGPhase 31 trial
Active Trials
NCT00376077Completed32Est. Apr 2016
Rigel Pharmaceuticals
Rigel PharmaceuticalsSOUTH SAN FRANCISCO, CA
4 programs
Fostamatinib disodium 100 mgN/A1 trial
Fostamatinib DisodiumPHASE_31 trial
Fostamatinib DisodiumPHASE_31 trial
Fostamatinib disodiumPHASE_31 trial
Active Trials
NCT03363334No Longer Available
NCT02076412Completed74Est. Aug 2016
NCT02077192Completed123Est. Jun 2020
+1 more trials
GSK
GSKLONDON, United Kingdom
2 programs
EltrombopagN/A1 trial
EltrombopagPHASE_3
Active Trials
NCT01439321Completed280Est. Jun 2011
CSL Behring
CSL BehringIL - Bradley
2 programs
Immunoglobulin IntravenousPHASE_31 trial
IgPro10PHASE_41 trial
Active Trials
NCT00168038Completed58Est. Feb 2006
NCT01390649Completed57Est. Sep 2014
Bristol Myers Squibb
1 program
BMS-986004 75 mg IVPHASE_1_21 trial
Active Trials
NCT02273960Completed46Est. Jan 2018
Swedish Orphan Biovitrum
1 program
Sym001PHASE_21 trial
Active Trials
NCT00718692Completed61Est. Oct 2011
Biogen
BiogenCAMBRIDGE, MA
1 program
Rituxan, Cyclophosphamide, Vincristine, PrednisonePHASE_2_3
Octapharma
OctapharmaAustria - Vienna
1 program
Octagam 10%PHASE_31 trial
Active Trials
NCT00426270Completed116Est. Sep 2008

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
CSL BehringIgPro10
Rigel PharmaceuticalsFostamatinib Disodium
Rigel PharmaceuticalsFostamatinib Disodium
Rigel PharmaceuticalsFostamatinib disodium
SandozEltrombopag
OctapharmaOctagam 10%
BayerMethylprednisolone and IVIG
CSL BehringImmunoglobulin Intravenous
Swedish Orphan BiovitrumSym001
Bristol Myers SquibbBMS-986004 75 mg IV
GSKEltrombopag

Clinical Trials (12)

Total enrollment: 997 patients across 12 trials

A Safety Study of Intravenous Immunoglobulin in Patients With Chronic Immune Thrombocytopenic Purpura (ITP)

Start: Nov 2011Est. completion: Sep 201457 patients
Phase 4Completed

A Efficacy and Safety Study of Fostamatinib in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)

Start: Jan 2015Est. completion: Aug 201674 patients
Phase 3Completed

Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)

Start: Oct 2014Est. completion: Jun 2020123 patients
Phase 3Completed

A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)

Start: Jul 2014Est. completion: Apr 201676 patients
Phase 3Completed

A Trial of Eltrombopag or Intravenous Immune Globulin Before Surgery for Immune Thrombocytopenia Patients

Start: Oct 2012Est. completion: Aug 201974 patients
Phase 3Completed

Clinical Study to Evaluate the Efficacy and Safety of Octagam 10% in Idiopathic Thrombocytopenic Purpura in Adults

Start: Jun 2006Est. completion: Sep 2008116 patients
Phase 3Completed
NCT00376077BayerMethylprednisolone and IVIG

A Randomized Study of IVIG vs. IVIG With High Dose Methylprednisolone in Childhood ITP.

Start: Aug 2005Est. completion: Apr 201632 patients
Phase 3Completed
NCT00168038CSL BehringImmunoglobulin Intravenous

Treatment of Chronic Immune Thrombocytopenic Purpura (ITP) With Intravenous Immunoglobulin IgPro10

Start: Dec 2004Est. completion: Feb 200658 patients
Phase 3Completed

Open Label Trial on the Safety and Efficacy of Sym001 in the Treatment of Immune Thrombocytopenic Purpura (ITP)

Start: Jul 2008Est. completion: Oct 201161 patients
Phase 2Completed

Study to Evaluate Safety and Efficacy in Adult Subjects With ITP

Start: Nov 2014Est. completion: Jan 201846 patients
Phase 1/2Completed
NCT03363334Rigel PharmaceuticalsFostamatinib disodium 100 mg

Expanded Access of Fostamatinib in Patients With Persistent or Chronic Relapsing/Refractory ITP

N/ANo Longer Available
NCT01439321GSKEltrombopag

Outcomes Comparison of Chronic Immune Thrombocytopenic Purpura (ITP) Patients Switched to Eltrombopag and Romiplostim

Start: Nov 2010Est. completion: Jun 2011280 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

4 late-stage (Phase 3) programs, potential near-term approvals
12 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.